In a long-term cohort study enrolling 6,928 subjects treated with GH in France, Carel et al. reported ~33% higher all-cause mortality in the subjects treated with GH, which was mainly attributed to the incidence of bone tumors and intracerebral hemorrhages (56). The gene discussed is GH1; the disease is bone neoplasm.